BCPC Balchem Corporation

Balchem Corporation Acquires Bioscreen Technologies, S.r.l.

Balchem Corporation Acquires Bioscreen Technologies, S.r.l.

NEW HAMPTON, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), through its wholly owned subsidiary, Balchem Italia S.r.l., today acquired Bioscreen Technologies, S.r.l., a small privately held manufacturer of encapsulated and fermented feed nutrition ingredients, headquartered in Bertinoro, Italy. The financial terms of the transaction were not disclosed. 

Bioscreen manufactures high-performance encapsulates and fermented products that deliver value-added solutions to an international animal nutrition and health customer base. Launched in 2005, Bioscreen has focused on developing and marketing new and improved technologies to meet customer needs.

Bioscreen’s existing business will be integrated within Balchem’s Animal Nutrition & Health business segment. The Animal Nutrition & Health segment provides a growing portfolio of encapsulated nutrients, choline products and chelated minerals including ReaShure®, NitroShureTM, AminoShure®, NiaShureTM, PetShureTM and KeyShure®. With a focus on improving productivity and profitability, this segment is leading the charge to meet the nutritional needs of ruminants, monogastrics and companion animals.

“We are very excited to bring Bioscreen’s manufacturing, technical and commercial capabilities into our company. While Bioscreen does not bring significant existing business to Balchem, this acquisition provides a European manufacturing platform for Balchem’s encapsulated nutrients and will allow us to accelerate our growth within Europe,” said Jonathan Griffin, Vice President and General Manager, Animal Nutrition & Health.

Griffin added, “The addition of local European manufacturing capabilities for our encapsulated products, to our existing European Choline manufacturing footprint, further strengthens our ability to bring a broad range of health and nutrition solutions to our European customers.”

Segment Information

Balchem Corporation reports four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications.

Forward-Looking Statements

This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2017. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date

Contact:           

Terry Coelho, Balchem Corporation

(845) 326-5600 /

EN
29/08/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Balchem Corporation

 PRESS RELEASE

Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financia...

Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025. For the quarter, the Company reported net sales of $263.6 million, net earnings of $39.2 million, adjusted EBITDA(a) of $67.9 million, and free cash flow(a) of $51.2 million. For the full year 2025, the Company reported net sales of $1.037 billion, net earnings of $154.8 million, adjusted EBITDA of $274.9 million, and fre...

 PRESS RELEASE

Balchem Corporation Announces Quarterly Conference Call for Fourth Qua...

Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2025 Financial Results on February 20, 2026 MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year 2025 results will be published prior to the market opening on Friday, February 20...

 PRESS RELEASE

Balchem Corporation to Attend the CJS Securities 26th Annual New Ideas...

Balchem Corporation to Attend the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026 MONTVALE, N.J., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will ...

 PRESS RELEASE

Statement on new EU choline chloride anti-dumping measures

Statement on new EU choline chloride anti-dumping measures EU producers laud EU for addressing choline chloride dumping by China; measures will help preserve jobs and secure feed supply chain MONTVALE, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- As producers of choline chloride in the EU, Eastman and Balchem welcome the European Union's decision published on December 19, 2025 to adopt anti-dumping duties between 90.0 and 115.9% on choline chloride imports from the People's Republic of China. This decision, which will be effective for five years with the possibility of renewal, confirms Euro...

 PRESS RELEASE

Balchem Corporation Announces Dividend

Balchem Corporation Announces Dividend MONTVALE, N.J., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that on December 9, 2025, its Board of Directors declared a dividend on its shares of common stock equal to $0.96 per share on the Company’s issued and outstanding Common Stock, to be payable on January 20, 2026 to stockholders of record at the close of business on December 23, 2025. This dividend represents an 10.3% increase over last year’s annual dividend. Ted Harris, Balchem’s Chairman, President and CEO, said, “Balchem has a longstanding commitm...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch